Difference between revisions of "Team:CPU CHINA/HP/Gold Integrated"
Ser Archer (Talk | contribs) |
Ser Archer (Talk | contribs) |
||
| (32 intermediate revisions by the same user not shown) | |||
| Line 90: | Line 90: | ||
} | } | ||
| − | # | + | #video2,#video3,.ted-txt,.club-txt |
| + | { | ||
| + | display:none; | ||
| + | width:95%; | ||
| + | position:relative; | ||
| + | top:10px; | ||
| + | height:80%; | ||
| + | line-height:3.5rem; | ||
| + | font-size:1.5rem !important; | ||
| + | } | ||
| + | |||
| + | .patients-txt | ||
{ | { | ||
display:none; | display:none; | ||
| Line 231: | Line 242: | ||
<div id="hp-block2" class="hp-block" style="display:none;"> | <div id="hp-block2" class="hp-block" style="display:none;"> | ||
<div class="page_content" style="text-align:center;font-family:'Century Gothic';"> | <div class="page_content" style="text-align:center;font-family:'Century Gothic';"> | ||
| − | <div style="width:100%"><h2 id="hp-block2-head">Business investigations of Rig</h2></div> | + | <div style="width:100%"><a href="https://static.igem.org/mediawiki/2018/c/cb/T--CPU_CHINA--hp-shangyejihuashu.pdf"><h2 id="hp-block2-head">Business investigations of Rig</a></h2></div> |
| − | <div id="club-txt1" class="club-txt" style="text-align:left;font-size:1.2em;display:block;">We evaluated the feasibility of building a business case and commercializing our conditional RNAi system. This started with our interview with several experts in this field. Based on their suggestions, we then tried to add a mathematical model to simulate the progression of liver cancer and the cost-effectiveness of our product. And we have drawn up a business plan to summarize the points we considered of the entrepreneurship of our project. | + | <div id="club-txt1" class="club-txt" style="text-align:left;font-size:1.2em;display:block;">We evaluated the feasibility of building a business case and commercializing our conditional RNAi system. This started with our interview with several experts in this field. Based on their suggestions, we then tried to add a mathematical model to simulate the progression of liver cancer and the cost-effectiveness of our product. And we have drawn up a business plan to summarize the points we considered of the entrepreneurship of our project.<br>(Tips:Please Click On Our Title TO See Our <a href="https://static.igem.org/mediawiki/2018/c/cb/T--CPU_CHINA--hp-shangyejihuashu.pdf">Entrepreneurship_Proposal</a> ) |
<p><a id="1" onclick="turnToNext2(this.id)">[Read more]</a></p> | <p><a id="1" onclick="turnToNext2(this.id)">[Read more]</a></p> | ||
</div> | </div> | ||
| Line 316: | Line 327: | ||
<div id="club-txt16" class="club-txt" style="text-align:left;font-size:1.2em;"> | <div id="club-txt16" class="club-txt" style="text-align:left;font-size:1.2em;"> | ||
| − | <video id=" | + | <video id="video2" style="display:none;" controls="controls" preload="preload" loop="loop"> |
<source src="https://static.igem.org/mediawiki/2018/a/a7/T--CPU_CHINA--hp-gold.mp3" type="video/mp3"/> | <source src="https://static.igem.org/mediawiki/2018/a/a7/T--CPU_CHINA--hp-gold.mp3" type="video/mp3"/> | ||
<source src="https://static.igem.org/mediawiki/2018/7/74/T--CPU_CHINA--hp-gold.mp4" type="video/mp4"/> | <source src="https://static.igem.org/mediawiki/2018/7/74/T--CPU_CHINA--hp-gold.mp4" type="video/mp4"/> | ||
| Line 328: | Line 339: | ||
</div> | </div> | ||
| − | <!--*********************************** | + | |
| + | <!--***********************************癌友会************************************ --> | ||
<div id="hp-block3" class="hp-block" style="display:none;"> | <div id="hp-block3" class="hp-block" style="display:none;"> | ||
<div class="page_content" style="text-align:center;font-family:'Century Gothic';"> | <div class="page_content" style="text-align:center;font-family:'Century Gothic';"> | ||
| − | <h2> | + | <div style="width:100%;"><h2>Interview with a Liver Metastasis Patient</h2> |
| − | + | ||
</div> | </div> | ||
| + | <div id="patients-txt1" class="patients-txt" style="display:block !important;text-align:left;font-size:1.2em;"> | ||
| + | To truly understand how our project could be of benefit to patients, we got in touch with the biggest cancer patients’ community of Southeast China: the Nanjing Cancer Rehabilitation Association. We joined one of their events and communicated with the patients. | ||
| + | Nanjing Cancer Rehabilitation Association is a non-profit organization composed of cancer patients and volunteers. Currently there are 9,668 registered members in the association. Regular activities include lectures given by professionals and Sharing Circles during which members of this association share their experience with the disease. Those who are of better health even provide counseling services for other patients. | ||
| + | |||
| + | <p><a id="1" onclick="turnToNext3(this.id)">[Read more]</a></p> | ||
| + | </div> | ||
| + | |||
| + | <div id="patients-txt2" class="patients-txt" style="text-align:left;font-size:1.2em;"> | ||
| + | On September 19th, Huandi Xu, Hongyu Wang and Yunge Lou went to Baima Park, Nanjing to join an event held by patients who regained their health from cancer. Talented members prepared entertainments for everyone. Several people shared their stories of fighting against cancer. | ||
| + | One of the patients we interviewed, a Mr. Liu, received novel therapy during the 90s and luckily survived all these years. As a beneficiary of the bio-therapy, he really inspired us and helped us to compassionately feel the significance of new treatments. | ||
| + | |||
| + | <p><a id="2" onclick="turnToNext3(this.id)">[Read more]</a>  <a id="-2" onclick="turnBack3(this.id)">[Backwards]</a></p> | ||
| + | </div> | ||
| + | |||
| + | <div id="patients-txt3" class="patients-txt" style="text-align:left;font-size:1.2em;"> | ||
| + | Mr. Liu was diagnosed with gastric cancer in 1995 and received resection immediately. However, six months after that the cancer was found to have metastasized to his liver. Even worse, the cancer cells soon spread among the two liver lobes and made it impossible to perform surgery. | ||
| + | He sought treatment in several different hospitals but most of the doctors were pessimistic enough to suggest that he give up. But he didn’t. At last he heard that there was a new bio-therapy in PLA 454th Hospital. At that time, the bio-therapy was still in clinical trial and patients suffered grave pain during the treatment. | ||
| + | |||
| + | <p><a id="3" onclick="turnToNext3(this.id)">[Read more]</a>  <a id="-3" onclick="turnBack3(this.id)">[Backwards]</a></p> | ||
| + | </div> | ||
| + | |||
| + | <div id="patients-txt4" class="patients-txt" style="text-align:left;font-size:1.2em;"> | ||
| + | Having no other choice, Mr. Liu chose to try out the new therapy, though there was no legal insurance and no guarantee was made. During that time, he regularly received interferon and other biologicals, hoping to kill the cancer. After 2 years of such practice, he surprisingly found that the tumor tissues had vanished and he became cancer-free. And now it’s 2018. Over the years, his recovery has become a legendary example of victory against cancer, inspiration for doctors and alike patients. Mr. Liu also described to our team members the torture and possible side effects that could be brought by chemo-therapy. He believes that our highly specific strategy would actually be of benefit and reduce the suffering of cancer patients, which truly encouraged us. | ||
| + | <p><a id="4" onclick="turnToNext3(this.id)">[Read more]</a>  <a id="-4" onclick="turnBack3(this.id)">[Backwards]</a></p> | ||
| + | </div> | ||
| + | |||
| + | <div id="patients-txt5" class="patients-txt" style="text-align:left;font-size:1.2em;"> | ||
| + | Mr. Liu emphasized on the significance of a drug’s specificity. He himself endured the side effects of chemotherapy as it also damaged his healthy organs. During his visits to other cancer patients, he also noticed other side effects such as hair loss and dermatitis. Those effects not only lower the life quality of the patients, but more importantly reduce their confidence towards cancer. In this way, his interview gave us a more intuitive understanding of the strong side effects of chemotherapy and the implication that there is an urgent need for high specificity drugs.<p><a id="5" onclick="turnToNext3(this.id)">[Read more]</a>  <a id="-5" onclick="turnBack3(this.id)">[Backwards]</a></p> | ||
| + | </div> | ||
| + | |||
| + | <div id="patients-txt6" class="patients-txt" style="text-align:left;font-size:1.2em;"> | ||
| + | Mr. Liu has his own opinions on new cancer therapies. Before this interview, we weren’t very confident about our project as it was based on a new theory. Mr. Liu’s words encouraged us. He said that he strongly supports novel therapies as he himself is a direct beneficiary of such. And he assures the team that the general public are accepting the idea of new bio-therapies. As technology develops, new therapies will show more of their advantages. If new projects can well pass the clinical trials, they will eventually become recognized by the patient.(<a href="javascript:void(0)" onclick=turnToNext3(6)>Click here to see the video</a>) | ||
| + | <p><a id="-6" onclick="turnBack3(this.id)">[Backwards]</a></p> | ||
| + | </div> | ||
| + | |||
| + | <div id="patients-txt7" class="patients-txt" style="text-align:left;font-size:1.2em;"> | ||
| + | <video id="video3" style="display:none;" controls="controls" preload="preload" loop="loop"> | ||
| + | <source src="https://static.igem.org/mediawiki/2018/9/9f/T--CPU_CHINA--hp-aiyou.mp3" type="video/mp3"/> | ||
| + | <source src="https://static.igem.org/mediawiki/2018/7/70/T--CPU_CHINA--hp-aiyou.mp4" type="video/mp4"/> | ||
| + | <source src="https://static.igem.org/mediawiki/2018/7/7a/T--CPU_CHINA--hp-aiyou.webm" type="video/webm"/> | ||
| + | Your browser does not support the video tag. | ||
| + | </video> | ||
| + | <p><a id="-7" onclick="turnBack3(this.id)">[Backwards]</a></p> | ||
| + | </div> | ||
</div> | </div> | ||
</body> | </body> | ||
| Line 383: | Line 438: | ||
/*********点击按钮跳转**********/ | /*********点击按钮跳转**********/ | ||
$("#scroll-1").click(function(){ | $("#scroll-1").click(function(){ | ||
| − | window.location.href="https://2018.igem.org/Team:CPU_CHINA/HP/ | + | window.location.href="https://2018.igem.org/Team:CPU_CHINA/HP/Gold_Integrated"; |
}) | }) | ||
$("#scroll-2").click(function(){ | $("#scroll-2").click(function(){ | ||
| Line 391: | Line 446: | ||
}) | }) | ||
$("#scroll-3").click(function(){ | $("#scroll-3").click(function(){ | ||
| − | + | $("#hp-block1").hide(); | |
| + | $("#hp-block2").hide(); | ||
| + | $("#hp-block3").show(); | ||
| + | $(".patients-txt").hide(); | ||
| + | $("#patients-txt1").show(); | ||
}) | }) | ||
$(".scroll-btn").click(function(){ | $(".scroll-btn").click(function(){ | ||
| − | var | + | var v2 = document.getElementById("video2"); |
| − | + | v2.pause(); | |
}) | }) | ||
/*****************点击链接readmore/backwards******************/ | /*****************点击链接readmore/backwards******************/ | ||
| Line 415: | Line 474: | ||
$(".club-txt").hide(); | $(".club-txt").hide(); | ||
$("#club-txt"+id).show(); | $("#club-txt"+id).show(); | ||
| + | if(id==15) | ||
| + | $("#video2").show(); | ||
} | } | ||
function turnBack2(id){ | function turnBack2(id){ | ||
| + | $("#video2").hide(); | ||
id=Math.abs(id); | id=Math.abs(id); | ||
id--; | id--; | ||
| Line 422: | Line 484: | ||
$("#club-txt"+id).show(); | $("#club-txt"+id).show(); | ||
} | } | ||
| + | |||
| + | function turnToNext3(id){ | ||
| + | id++; | ||
| + | $(".patients-txt").hide(); | ||
| + | $("#patients-txt"+id).show(); | ||
| + | if(id==6) | ||
| + | $("#video3").show(); | ||
| + | } | ||
| + | function turnBack3(id){ | ||
| + | $("#video3").hide(); | ||
| + | id=Math.abs(id); | ||
| + | id--; | ||
| + | $(".patients-txt").hide(); | ||
| + | $("#patients-txt"+id).show(); | ||
| + | } | ||
| + | |||
| + | function getQueryVariable(){ | ||
| + | //获得当前url地址的?后面的部分 | ||
| + | var query = window.location.search.substring(1); | ||
| + | query=decodeURI(query); | ||
| + | //从?开始往后的部分 | ||
| + | var x=query.split('='); | ||
| + | |||
| + | return x[0]; | ||
| + | } | ||
| + | |||
| + | $(document).ready(function(){ | ||
| + | if(getQueryVariable()=='business'){$("#scroll-2").click();} | ||
| + | else if(getQueryVariable()=='patients'){$("#scroll-3").click();} | ||
| + | }) | ||
</script> | </script> | ||
</html> | </html> | ||
Latest revision as of 14:35, 6 December 2018
Why do we apply HCC ?
Our business plan!
Our communication with a cancer patient!
An interview with a doctor
Date: May 24th，2018
When choosing the disease to apply our project, we initially decided to target at liver cancer. In order to understand current treatment of liver cancer, we interviewed Director Zhou Guoping of Jiangsu Cancer Hospital. Director Zhou Guoping has decades of clinical experience in the treatment of liver cancer. He introduced us to the situation of liver cancer in China, the characteristics of liver cancer and treatment methods. The interview excerpt is as following.
When choosing the disease to apply our project, we initially decided to target at liver cancer. In order to understand current treatment of liver cancer, we interviewed Director Zhou Guoping of Jiangsu Cancer Hospital. Director Zhou Guoping has decades of clinical experience in the treatment of liver cancer. He introduced us to the situation of liver cancer in China, the characteristics of liver cancer and treatment methods. The interview excerpt is as following.
Q：We understand that most patients with liver cancer are already in the advanced stage when they are diagnosed. Is it true in your experience? Does this mean that most patients with liver cancer are difficult to cure and they have been sentenced to death?
A: The incidence of liver cancer has always been very high in our country, especially in men. Because of the high incidence of hepatitis B in China, the incidence of liver cancer is relatively high. Liver cancer in China has a lot to do with hepatitis B. When someone is diagnosed with liver cancer, the mortality rate is really high. It is rare for the patients to be diagnosed with small tumor which means the diameter of the tumor is less than 3cm. The survival rate of patients with small tumor generally is quite high. However, they are often diagnosed at the middle or advanced stages. The cancer can bring many other problems, such as ascites, jaundice, etc. which causes difficulties in treatment. At present, the best treatment for liver cancer is surgery, but most people can not undergo the surgery.
A: The incidence of liver cancer has always been very high in our country, especially in men. Because of the high incidence of hepatitis B in China, the incidence of liver cancer is relatively high. Liver cancer in China has a lot to do with hepatitis B. When someone is diagnosed with liver cancer, the mortality rate is really high. It is rare for the patients to be diagnosed with small tumor which means the diameter of the tumor is less than 3cm. The survival rate of patients with small tumor generally is quite high. However, they are often diagnosed at the middle or advanced stages. The cancer can bring many other problems, such as ascites, jaundice, etc. which causes difficulties in treatment. At present, the best treatment for liver cancer is surgery, but most people can not undergo the surgery.
Q：What kind of treatment is currently used in clinical practice?
A: Because most patients lose their chance of surgery, and the recurrence rate of this kind of cancer is really high. At present, chemotherapy is commonly used. The chemotherapy efficiency of liver cancer in the past is very poor. In the last two years, it was slightly improved due to technology improvement. In addition there are embolization treatment and targeted therapy, such as sorafenib. However, according to the score system we use now, in fact, the use of sorafenib in the advanced stage have barely any effects, like a comfort treatment. However, sorafenib is still the drug of first choice for advanced treatment.
A: Because most patients lose their chance of surgery, and the recurrence rate of this kind of cancer is really high. At present, chemotherapy is commonly used. The chemotherapy efficiency of liver cancer in the past is very poor. In the last two years, it was slightly improved due to technology improvement. In addition there are embolization treatment and targeted therapy, such as sorafenib. However, according to the score system we use now, in fact, the use of sorafenib in the advanced stage have barely any effects, like a comfort treatment. However, sorafenib is still the drug of first choice for advanced treatment.
Q：What are the characteristics of liver cancer compared to other cancers?
A: Liver cancer cells are active and invasive, and there are rich sinusoids surround them. So the liver cancer cells can easily invade the capsule and blood vessels, resulting in easy local spread of the tumor, bloody metastasis. To a certain extent, for the liver is the main metabolic organ, the impaired liver function affects metabolism greatly. The side effects of taking medicine can be greater than others.
A: Liver cancer cells are active and invasive, and there are rich sinusoids surround them. So the liver cancer cells can easily invade the capsule and blood vessels, resulting in easy local spread of the tumor, bloody metastasis. To a certain extent, for the liver is the main metabolic organ, the impaired liver function affects metabolism greatly. The side effects of taking medicine can be greater than others.
Q：What do you think of gene therapy for liver cancer? Is it promising for our RNAi strategy to be applied?
A：There is no mature gene therapy for liver cancer till now. However, we still need new treatment methods for liver cancer. If you have done quite well in your experiments, it will be really promising. The high specificity could reduce the side effects greatly, which is very significant.
A：There is no mature gene therapy for liver cancer till now. However, we still need new treatment methods for liver cancer. If you have done quite well in your experiments, it will be really promising. The high specificity could reduce the side effects greatly, which is very significant.
In this interview, Director Zhou help us to understand the difficulties and features of the treatment in liver cancer. Then he expressed his expectation to our project. He said that clinically, advanced liver cancer lacks more effective targeted drugs. Although the traditional therapy has been improving, but it does not turn out well. He strongly encourages us to try to apply our ideas in the treatment of liver cancer.
